In:
International Cardiovascular Forum Journal, International Cardiovascular Forum Journal, Vol. 4 ( 2015-12-04), p. 71-
Abstract:
〈 p 〉 Patients scheduled for atrial fibrillation (AF) cardioversion were excluded from clinical trials of novel oral anticoagulants (NOACs). 〈 /p 〉 〈 p 〉 We evaluated efficacy and safety of NOACs in patients undergoing electrical cardioversion for AF. 〈 /p 〉 〈 p 〉 We performed a monocentric study of all patients on NOACs who underwent elective electrical cardioversion for non-valvular AF between January 2012 and December 2014. We analyzed incidence of stroke and bleeding at 30 days. 〈 /p 〉 〈 p 〉 Fifty patients were included, 28 receiving dabigatran, 22 rivaroxaban. Mean age was 65 ± 12 years. Mean CHADS2-VA2SC and HASBLED scores were 3 ± 1.8 and 2.2 ± 1.1 respectively. Transoesophageal echocardiography was performed in 41 (79%) patients, revealing a thrombus in 2 (5%). No clinical evidence of stroke occurred in the 30 days, 1 major gastrointestinal bleeding (2%) in patient on rivaroxaban (led to premature discontinuation) and 3 minor bleedings. 〈 /p 〉 〈 p 〉 NOACs seem to be safe in daily practice of electrical cardioversion in our population. 〈 /p 〉
Type of Medium:
Online Resource
ISSN:
2409-3424
,
2410-2636
DOI:
10.17987/icfj.v4i0.148
Language:
Unknown
Publisher:
International Cardiovascular Forum Journal
Publication Date:
2015
detail.hit.zdb_id:
2855971-X
Permalink
